Press release
Coeptis (NASDAQ: COEP) Accelerates Growth with Strategic Partnerships and Innovation
Recently, Coeptis, Inc. (NasdaQ: COEP) has taken a bold step into the future of blockchain-driven digital marketing with its latest partnership with Arketyp Valu, a key developer within the Verus Project, which has recently achieved a market capitalization exceeding $500 million. This strategic alliance aims to integrate NexGenAI's advanced digital marketing solutions into ValuSocial, an upcoming platform designed to revolutionize engagement through AI-driven marketing and scalable Public Blockchains as a Service (PBaaS) powered by Verus Coin.ValuSocial: Redefining Digital Marketing with AI and Blockchain
The innovative ValuSocial platform represents the next evolution in decentralized digital marketing. By leveraging NexGenAI's state-of-the-art marketing tools, businesses and individuals can launch targeted campaigns that utilize AI automation, blockchain security, and tokenized engagement. This integration merges AI-driven marketing strategies with Verus Coin's advanced blockchain framework, providing unparalleled scalability and transparency.
Nicholas Lyons, CEO of Arketyp Valu, expressed enthusiasm about the collaboration, stating, "This partnership effectively merges the latest in digital marketing innovation with the reliable and scalable framework of the Verus network, heralding a new era of global digital engagement."
Coeptis CEO Dave Mehalick emphasized the groundbreaking nature of this venture, adding, "By combining our expertise with Arketyp Valu's blockchain-powered offerings, we are setting the foundation for a decentralized, interconnected digital ecosystem that will redefine how businesses and consumers interact."
Expanding Coeptis' Reach: AI, Blockchain, and Next-Gen Solutions
This collaboration with Arketyp Valu is part of Coeptis' broader vision to integrate artificial intelligence, blockchain, and biotech innovations into its growing portfolio. Recent strategic moves include:
*
Exclusive License to GEAR Trademark Cell Therapy: A breakthrough approach in cancer treatment leveraging genetically modified natural killer (NK) cells to enhance deep remission in patients with hematologic malignancies and solid tumors.
*
Partnership with MarketLeverage: Merging AI-powered analytics with performance-based marketing strategies to drive efficiency and conversions across 5,500 advertisers and 55,000 publishers.
*
Collaboration with NUBURU, Inc. (NYSE: BURU): Advancing AI-driven technologies into defense-tech, security, and operational resilience sectors.
A High-Growth Opportunity for Investors and Traders
Coeptis' expanding footprint in blockchain, AI, and biotechnology presents a compelling investment opportunity. The company's ability to innovate across multiple high-growth industries makes COEP an attractive stock for investors looking to capitalize on the convergence of digital transformation and life sciences.
With the ValuSocial platform set to disrupt digital marketing and Coeptis leading advancements in biotechnology, AI, and blockchain, this is a pivotal moment for traders and investors to take notice.
For Traders and investors looking for a company at the nexus of biotech, AI, and digital transformation, Coeptis represents a high-potential opportunity. With exclusive biotech advancements, pioneering AI-driven partnerships, and a commitment to innovation, COEP is well-positioned to deliver significant value creation in the coming years.
Read more by visiting COEP's website [https://coeptistx.com/].
Stay ahead of the curve-keep an eye on Coeptis, Inc. (Nasdaq: COEP) as it continues its path toward groundbreaking success. Other notable AI stocks to keep on top of radar include Microsoft Corporation (NASDAQ: MSFT), NVIDIA Corporation (NASDAQ: NVDA), Amazon.com, Inc. (NASDAQ: AMZN), Alphabet Inc. (NASDAQ: GOOGL), Meta Platforms, Inc. (NASDAQ: META), Broadcom Inc. (NASDAQ: AVGO)
Disclaimer: This blog post is for informational purposes only and does not constitute financial advice or an endorsement of COEP or its strategies. FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Please ensure to fully read and comprehend our disclaimer found at https://UsaStockReport.com//disclaimer/. https://UsaStockReport.com/ [https://digitalcoinstandard.com/] has been compensated five hundred dollars by a 3rd party Carriage Consulting Group for content distribution services on COEP for March 17th, 2025. https://UsaStockReport.com/ is neither an investment advisor nor a registered broker. No current owner, employee, or independent contractor of https://UsaStockReport.com/ is registered as a securities broker-dealer, broker, investment advisor, or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. This article may contain forward-looking statements as defined under Section 27A of the Securities Act of 1933 and 21E of the Exchange Act of 1934. These statements, often incorporating terms like "believes," "anticipates," "estimates," "expects," "projects," "intends," or similar expressions about future performance or conduct, are based on present expectations, estimates, and projections, and are not historical facts. They carry various risks and uncertainties that may result in significant deviation from the anticipated results or events. Past performance does not guarantee future results.https://UsaStockReport.com/ does not commit to updating forward-looking statements based on new information or future events. Readers are encouraged to review all public SEC filings made by the profiled companies at https://www.sec.gov/edgar/searchedgar/companysearch. It is always important to conduct thorough due diligence and exercise caution in trading.https://UsaStockReport.com/ is not managed by a licensed broker, a dealer, or a registered investment adviser. The content here is purely informational and should not be taken as investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor regarding forward-looking statements. Any statement that projects, foresees, expects, anticipates, estimates, believes, or understands certain actions to possibly occur are not historical facts and may be forward-looking statements. These statements are based on expectations, estimates, and projections that could cause actual results to differ greatly from those anticipated. Investing in micro-cap and growth securities is speculative and entails a high degree of risk, potentially leading to a total or substantial loss of investment. Please note that no content published here constitutes a recommendation to buy or sell a security. It is solely informational, and you should not construe it as legal, tax, investment, financial, or other advice. No content in this article constitutes an offer or solicitation by https://UsaStockReport.com/ or any third-party service provider to buy or sell securities or other financial instruments. The content in this article does not address the circumstances of any specific individual or entity and does not constitute professional and/or financial advice. https://UsaStockReport.com/ is not a fiduciary by virtue of any person's use of or access to this content.
Sources:
https://www.theglobeandmail.com/investing/markets/stocks/COEP/pressreleases/31027428/coeptis-nexgenai-partners-with-arketyp-valu-to-revolutionize-digital-engagement-on-the-verus-network/#:~:text
https://finance.yahoo.com/news/coeptis-therapeutics-secures-worldwide-development-123400980.html
https://finance.yahoo.com/news/coeptis-nexgenai-affiliates-partners-nuburu-133700828.html
https://finance.yahoo.com/news/coeptis-nexgenai-affiliates-network-marketleverage-122700809.html
https://finance.yahoo.com/news/coeptis-therapeutics-leverages-artificial-intelligence-130900942.html
Media Contact
Company Name: UsaStockReport
Contact Person: Ash K
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=coeptis-nasdaq-coep-accelerates-growth-with-strategic-partnerships-and-innovation]
City: Frisco
State: Texas
Country: United States
Website: https://usastockreport.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Coeptis (NASDAQ: COEP) Accelerates Growth with Strategic Partnerships and Innovation here
News-ID: 3918304 • Views: …
More Releases from ABNewswire

How to Pick the Best Online Chemistry Tutoring Platform
Image: https://www.abnewswire.com/upload/2025/10/814f4b38d9855ce5fcc0509bfebaa240.jpg
Choosing the right chemistry tutoring platform can make the difference between academic success and continued struggles with complex reactions and molecular structures. With students increasingly turning to digital solutions for personalized learning support, the online chemistry tutoring market has exploded with options promising everything from AI-powered progress tracking to virtual lab experiences that transform how learners approach this challenging subject.
Essential Platform Features for Effective Online Chemistry Tutoring
Modern chemistry tutoring…

Chronic Myeloid Leukemia Pipeline Drugs Report 2025: Emerging Therapies, Clinica …
DelveInsight's "Chronic Myeloid Leukemia Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in the Chronic Myeloid Leukemia pipeline landscape. It covers the Chronic Myeloid Leukemia Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Chronic Myeloid Leukemia Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Curious…

Diabetic Retinopathy Pipeline Drugs Report 2025: Emerging Therapies, Clinical De …
DelveInsight's, "Diabetic Retinopathy Pipeline Insights 2025" report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in the Diabetic Retinopathy pipeline landscape. It covers the Diabetic Retinopathy pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Diabetic Retinopathy pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by…

Diabetic Macular Edema Pipeline Outlook Report 2025: Emerging Therapies, Clinica …
DelveInsight's, "Diabetic Macular Edema Pipeline Insight 2025" report provides comprehensive insights about 45+ companies and 50+ pipeline drugs in Diabetic Macular Edema pipeline landscape. It covers the Diabetic Macular Edema pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Diabetic Macular Edema pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our…
More Releases for Coeptis
COEPTIS (COEP) Expands Global Footprint with Strategic India Tech Hub
A Pivotal Move into India's Booming Tech Ecosystem Could Drive Significant Growth for NASDAQ-Listed Biotech Innovator
COEPTIS, Inc. (NASDAQ: COEP) recently announced a strategic expansion that could position the company for accelerated growth in the high-demand sectors of AI, blockchain technologies, and biotechnology. The company revealed the establishment of a new co-working technology hub in Bhubaneswar, India through a partnership with U.S.-based NexGenAI Solutions Group and Indian technology firm Ishvara Tech…
Coeptis Inc. (COEP) Expands Cancer Immunotherapy Portfolio with Exclusive GEAR C …
COEP forms GEAR Therapeutics, as a majority-owned subsidiary, to advance GEAR-modified natural killer (NK) cells into first-in-human studies for broad range of cancers and other therapeutic modalities
Coeptis Inc. (Nasdaq: COEP) has taken a bold step forward in the fight against cancer by securing exclusive worldwide development and commercialization rights to the groundbreaking GEAR Trademark (Gene Edited Antibody Resistant) Cell Therapy Platform. This acquisition positions Coeptis as a leader in innovative…
Natural Killer Cell Therapeutics Market Size, Growth, Industry Trends | Emergen …
The global Natural Killer (NK) Cell Therapeutics market is projected to grow significantly from USD 6.14 billion in 2024 to USD 184.01 billion by 2033, at an impressive compound annual growth rate (CAGR) of 45.90%. This rapid expansion is fueled by advancements in combination therapies, increased government support, and rising clinical trials in immunotherapy.
Download Free Exclusive Sample PDF@https://www.emergenresearch.com/request-sample/3618
Growing Popularity of Combination Therapies The NK cell therapeutics industry is experiencing a…
Coeptis Therapeutics (Nasdaq: COEP) Emerges as a Biopharma Innovator Leveraging …
Coeptis Secures Five New Clients With Total Contract Value of $1.7 Million Dollars With More On The Horizon Signaling AI-Driven Marketing Innovations in Biopharma for Coeptis.
Coeptis Therapeutics Holdings, Inc (NASDAQ: COEP)., headquartered in Wexford, Pennsylvania, has established itself as a visionary leader in the biopharmaceutical sector, driving transformative advancements in cell therapy platforms targeting cancer, autoimmune, and infectious diseases. The company has further enhanced its position by embracing artificial intelligence…
Quit Smoking Drugs Market Size, Latest Trends, Growth Rate, Key Drivers And Fore …
"The new report published by The Business Research Company, titled ""Quit Smoking Drugs Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033"", delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends.
As per the report, the quit smoking drugs market size has grown rapidly in recent years. It will grow from $34.86 billion…
Quit Smoking Drugs Market Share, Opportunities Analysis, Recent Trends, Regional …
The Business Research Company has updated its global market reports, featuring the latest data for 2024 and projections up to 2033
The Business Research Company offers in-depth market insights through Quit Smoking Drugs Global Market Report 2024, providing businesses with a competitive advantage by thoroughly analyzing the market structure, including estimates for numerous segments and sub-segments.
Market Size And Growth Forecast:
The quit smoking drugs market size has grown rapidly in recent…